Evidence map›Paper›PMID 42054783›Full record

ArticleGynecologic oncology2026

Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

Eliya K Shachar, Jordyn Silverstein, Lorna Kwan, Ritu Salani, Beth Y Karlan, Dana M Chase

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eliya K ShacharDepartment of Obstetrics and Gynecology, University of California, Los Angeles, CA, USA; Gray Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Jordyn SilversteinDivision of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, CA, USA.
Lorna KwanDepartment of Urology, University of California, Los Angeles, CA, USA.
Ritu SalaniDepartment of Obstetrics and Gynecology, University of California, Los Angeles, CA, USA.
Beth Y KarlanDepartment of Obstetrics and Gynecology, University of California, Los Angeles, CA, USA.
Dana M ChaseDepartment of Obstetrics and Gynecology, University of California, Los Angeles, CA, USA. Electronic address: DMChase@mednet.ucla.edu.

Funding

Patient-Centered Outcomes Research Training in Urologic and Gynecologic Cancers (PCORT UroGynCan)T32CA251072 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Beth Y. Karlan, MARK S. LITWIN · 2020 to 2026
$2.1M
NCI NIH HHS T32 CA251072
6 · The paper itself

Abstract

objectivesDisparities in clinical trial enrollment raise concerns about the generalizability of antibody-drug conjugate (ADC) efficacy in gynecologic cancers. We evaluated real-world survival outcomes across demographic subgroups and assessed concordance with pivotal trials, while contextualizing findings within ongoing challenges of underrepresentation.

methodsWe conducted a cohort study of patients with advanced gynecologic cancers treated with ADCs at a tertiary academic center (June 2019-September 2025). Primary outcomes were overall survival (OS) and progression-free survival (PFS) by age, race, and ethnicity. Secondary objectives examined ECOG performance status, line of therapy, and Area Deprivation Index. Exploratory analyses assessed treatment discontinuation secondary to toxicity. Survival was estimated using Kaplan-Meier methods with univariable and multivariable models.

resultsAmong 142 patients,105 received mirvetuximab soravtansine (MIRV), 34 trastuzumab deruxtecan (T-DXd), and 16 tisotumab vedotin (TV). Median age was 64.8 years; 66.9% identified as White, 12.7% Asian, 6.3% Black/African American, and 14.1% Other. Most patients were non-Hispanic/Latina (88.7%), while 11.3% identified as Hispanic/Latina. In unadjusted analyses, PFS varied by treatment line in the MIRV cohort (p = 0.04), while OS differed by ethnicity and performance status (p < 0.01). Performance status was also associated with OS in the T-DXd cohort (p = 0.01). These associations were not significant in multivariable models. Treatment discontinuation due to toxicity occurred in 17.6% and did not differ by subgroup.

conclusionsReal-world ADC outcomes were consistent with pivotal trials, with no independent survival differences by subgroup after adjustment. These findings support continued investigation of clinical and structural factors influencing outcomes.

Indexed as

Antineoplastic Agents, ImmunologicalGenital Neoplasms, FemaleImmunoconjugatesAgedAged, 80 and overAge FactorsAntibodies, Monoclonal, HumanizedCohort StudiesFemaleHumansMaytansineMiddle AgedProgression-Free SurvivalTrastuzumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalImmunoconjugatesMaytansinemirvetuximab soravtansineTrastuzumabAgeAntibody drug conjugatesEthnicityGynecologic cancerRaceUnderrepresented minorities

Identifiers

PMID42054783
PMCPMC13644882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.